Method for rapid in vitro synthesis of glycoproteins via recombinant production of n-glycosylated proteins in prokaryotic cell lysates
Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.
1. A method for synthesizing an N-glycosylated carrier protein for a bacterial O-antigen via coordinated transcription, translation, and N-glycosylation in vitro, the method comprising:
(i) transcribing and translating a carrier protein in a cell-free protein synthesis reaction comprising (a) a nucleic acid encoding the carrier protein, (b) a Campylobacter jejuni lipid-linked oligosaccharide (LLO) comprising a bacterial O-antigen, and (c) a lysate of a modified Escherichia coli strain comprising an oligosaccharyltransferase (OST), the carrier protein comprising an inserted consensus sequence, D/E-X 1 -N-X 2 -S/T, wherein X 1 and X 2 may be any natural or unnatural amino acid except proline;
(ii) N-glycosylating the carrier protein in the cell-free protein synthesis reaction at the inserted consensus sequence with the bacterial O-antigen via activity of the OST.
2. The method of claim 1 , wherein the bacterial O-antigen is from E. coli.
3. The method of claim 1 , wherein the bacterial O-antigen is from Franciscella tularensis.
4. The method of claim 1 , further comprising formulating the N-glycosylated carrier protein as a vaccine composition comprising the N-glycosylated carrier protein.
5. The method of claim 4 , wherein the vaccine composition further comprises an adjuvant.
6. The method of claim 1 , wherein the carrier protein is an engineered variant of E. coli maltose binding protein (MBP), or a detoxified variant of the toxin from Clostridium tetani , or a detoxified variant of the toxin from Corynebacterium diptheriae.
7. The method of claim 1 , wherein the OST a C. jejuni Pg1B, or a naturally occurring bacterial homolog of C. jejuni Pg1B.
8. The method of claim 1 , wherein the OST is an engineered variant of C. jejuni Pg1B or of a bacterial homolog of C. jejuni Pg1B.
9. The method of claim 1 , wherein the transcribing, translating, and N-glycosylating is performed in a single vessel.
10. The method of claim 1 , wherein the E. coli lysate is of an E. coli comprising an inactivating modification or deletion in the endogenous waaL gene.
11. The method of claim 1 , wherein the OST comprises Pg1B OST activity.
12. A method for cell-free production of a glycoprotein, the method comprising: (a) mixing a first Escherichia coli cell lysate comprising an oligosaccharyltransferase (OST) and a second E. coli cell lysate comprising a bacterial O-antigen to prepare a cell-free protein synthesis reaction, wherein the cell-free protein synthesis reaction further comprises a nucleic acid encoding a carrier protein; (b) transcribing and translating the carrier protein in the cell-free protein synthesis reaction, the carrier protein comprising an inserted consensus sequence, D/E-X 1 -N-X 2 -S/T, wherein X 1 and X 2 may be any natural or unnatural amino acid except proline; and (c)N-glycosylating the carrier protein in the cell-free protein synthesis reaction at the inserted consensus sequence with the bacterial O-antigen via OST activity to produce the glycoprotein.
13. The method of claim 12 , wherein the second cell lysate comprises the O-antigen as part of a lipid-linked oligosaccharide (LLO).
14. The method of claim 12 , further comprising formulating the glycoprotein as a vaccine composition.
15. The method of claim 14 , the vaccine composition further comprises an adjuvant.
16. The method of claim 12 , wherein the bacterial O-antigen is from E. coli , or is from Franciscella tularensis.
17. The method of claim 12 , wherein the carrier protein is an engineered variant of E. coli maltose binding protein (MBP), or is a detoxified variant of the toxin from Clostridium tetani , or is a detoxified variant of the toxin from Corynebacterium diptheriae.
18. The method of claim 12 , wherein the OST is C. jejuni Pg1B, a naturally occurring bacterial homolog of Campylobacter jejuni Pg1B, or an engineered variant of C. jejuni Pg1B or of a bacterial homolog of C. jejuni Pg1B.
19. The method of claim 12 , wherein the transcribing, translating, and N-glycosylating is performed in a single vessel.
20. The method of claim 12 , wherein the E. coli lysate is of an E. coli comprising an inactivating modification or deletion in the endogenous waaL gene.
21. The method of claim 12 where the OST comprises Pg1B OST activity.